| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
ID: ALA5272704
Max Phase: Preclinical
Molecular Formula: C17H14N4O
Molecular Weight: 290.33
Associated Items:
Representations
Canonical SMILES: Cc1cccc2c1n1cncc1c(=O)n2Cc1cccnc1
Standard InChI: InChI=1S/C17H14N4O/c1-12-4-2-6-14-16(12)21-11-19-9-15(21)17(22)20(14)10-13-5-3-7-18-8-13/h2-9,11H,10H2,1H3
Standard InChI Key: HSXSMQSDLMVYCV-UHFFFAOYSA-N
Associated Targets(Human)
GABRA5 Tclin GABA receptor alpha-5 subunit (699 Activities)
GABRA1 Tclin GABA receptor alpha-1 subunit (399 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Molecule Features
| Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
| Molecule Type: | Topical: No | First In Class: No | Black Box: No |
| Chirality: No | Availability: No | Prodrug: No |
Drug Indications
| MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
|---|
Mechanisms of Action
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Properties
| Molecular Weight: 290.33 | Molecular Weight (Monoisotopic): 290.1168 | AlogP: 2.40 | #Rotatable Bonds: 2 |
| Polar Surface Area: 52.19 | Molecular Species: NEUTRAL | HBA: 5 | HBD: 0 |
| #RO5 Violations: 0 | HBA (Lipinski): 5 | HBD (Lipinski): 0 | #RO5 Violations (Lipinski): 0 |
| CX Acidic pKa: | CX Basic pKa: 4.81 | CX LogP: 1.66 | CX LogD: 1.66 |
| Aromatic Rings: 4 | Heavy Atoms: 22 | QED Weighted: 0.57 | Np Likeness Score: -1.17 |
References
| 1. Károlyi BI, Potor A, Kapus GL, Fodor L, Bobok A, Krámos B, Magdó I, Bata I, Szabó G.. (2023) Novel imidazo[1,5-a]quinoxaline derivatives: SAR, selectivity and modeling challenges en route to the identification of an α5-GABAA receptor NAM., 80 [PMID:36549396] [10.1016/j.bmcl.2022.129107] |
Source
Source(1):